Jakafi (ruxolitinib tablets) — Cigna
Accelerated or Blast Phase Myeloproliferative Neoplasm
Initial criteria
- Patient age ≥ 18 years
- Patient has at least one disease-related symptom (e.g., fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis)
Approval duration
1 year